Bruna M. Zucchetti

São Paulo, Brazil, 545, Bela Vista
Sao Paulo, SP 01309001, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: May 21, 2026

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast cancer research and treatment

Published: November 22, 2025

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Journal: NPJ breast cancer

Published: November 02, 2025

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast (Edinburgh, Scotland)

Published: January 15, 2025

Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.

Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.

Journal: Breast cancer research and treatment

Published: November 12, 2024

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.

Journal: NPJ breast cancer

Published: March 20, 2024

Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.

Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 10, 2019

The role of histone deacetylase inhibitors in metastatic breast cancer.

The role of histone deacetylase inhibitors in metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: November 07, 2018

Peliosis Hepatis Simulates Liver Metastases.

Peliosis Hepatis Simulates Liver Metastases.

Journal: Journal of global oncology

Published: September 23, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026